The Latest Breaking News from FDA

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

Earlier this month, the FDA approved Eli Lilly's Zepbound, a drug similar to its diabetes drug Mounjaro but specifically advertised for weight loss.

It’s no secret that the rate cycle, combined with an AI frenzy, greatly helped mega cap stocks this past year, and greatly harmed small cap stocks in need of capital. But, there may have been some throwing out the baby with the bath water activity in small caps that are…

RSV rates — which tend to climb in the fall and winter months — are highest for children under the age of five.

Like many Americans struggling to lose weight, Marissa Montanino felt compelled to try Ozempic or one of the other new so-called "wonder drugs" described as revolutionary in the fight against obesity.

Eli Lily’s Zepbound will undercut its rivals’ pricing but still costs over $1,000 a month.

One common decongestant, phenylephrine, was found ineffective this fall. Doctors are skeptical about the rest of the over-the-counter cold cures lineup.

Antiseizure drugs levetiracetam and clobazam can cause a serious hypersensitivity reaction called drug reactions with eosinophilia and systemic symptoms (DRESS), the FDA said.

Shares in Dutch medical device manufacturer Philips plunged Wednesday after the US Food and Drug Administration warned that its new machine to help patients sleep risked overheating.

The pharma industry’s long-term solid outlook is driven by steady demand for drugs due to the rising frequency of chronic conditions and growing geriatric population coupled with rapid technological innovations. Hence, quality pharma stocks, CytomX Therapeutics (CTMX), Eton Pharmaceuticals (ETON), and GSK (GSK), might be solid investments now for potential…

Morning Markets December E-Mini S&P 500 futures (ESZ2 3) are down -0.17%, and Dec Nasdaq 100 E-Mini futures (NQZ2 3) are down -0.20%. Stock index futures this morning are under pressure on negative carryover from a decline in the Euro Stoxx 50 to a 1-week low. European stocks fell back...